10x Genomics (TXG) reports Q3: everything you need to know ahead of earnings
10x Genomics (TXG) will report Q3 earnings on Thursday. Last quarter, it beat revenue and EPS estimates, reporting $151M in revenue, down 12.6% YoY. Analysts expect flat YoY revenue this quarter. Peers Illumina and West Pharmaceutical Services reported mixed results. TXG shares are down 32.8% over the last month, with an average price target of $77.50.
How this was made
The 30-second read
Why it matters
Traders can use the consensus and the company’s historical tendency to meet revenue estimates to calibrate risk into the after-hours print, but the piece lacks new TXG disclosures (no fresh guidance, contract, or regulatory update).
Market read
Provides a practical earnings checklist for TXG: timing, consensus revenue direction (flat YoY), and the notion that estimates have been reconfirmed.
What to watch
The article does not discuss margins, cash burn, product mix, or guidance specifics beyond a general mention of prior guidance topping expectations, which are often the true drivers of post-earnings repricing.
Background
The article frames TXG’s upcoming Q3 earnings as a near-term catalyst, referencing last quarter’s revenue/EPS beat and current consensus for flat YoY revenue.
Ticker impact
10x Genomics (TXG) is set to report Q3 results Thursday after the close, with the article outlining consensus revenue expectations and recent estimate reconfirmations.
Likely pre-earnings positioning around whether TXG can hold flat YoY revenue expectations; downside risk if results or guidance disappoint versus the flat consensus.
The article provides a clear earnings timing catalyst (after-hours Thursday) and specific consensus framing (flat YoY revenue) but does not disclose any new TXG-specific fundamental update beyond the earnings preview.
Market effects
May influence sentiment across life-sciences tools and services around earnings season read-throughs, though the article’s peer examples are not new catalysts.
Limited, as the piece is US-focused and does not cite macro releases or cross-market shocks.
Low, since it is primarily a single-company earnings preview with US-listed peers mentioned for context.
Counterpoint
TXG’s recent underperformance versus peers could mean expectations are already low; even a modest beat on revenue or guidance could trigger a larger-than-typical reaction.
Key entities
- company10x Genomics
Subject of the article, scheduled to report Q3 results Thursday after market close.
- peerIllumina
Peer cited for Q3 results and subsequent stock reaction, used as a read-through context.
- peerWest Pharmaceutical Services
Peer cited for Q3 results and stock reaction, used as a read-through context.
